phrykt

Palvella Therapeutics, Inc. (PVLA): who owns it and who trades it

As of Nov 16, 2026, PVLA insiders reported 76 open-market sales worth $15.9M and 3 purchases worth $850K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was George M Jenkins (Director), with $7.7M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Palvella Therapeutics

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, PVLA insiders reported $850K of open-market purchases and $15.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$850K
3 trades, 2 people
Sales, 12 months
$15.9M
76 trades, 4 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 12, 2026

Purchases and sales by month

$4.9M$4.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Jeffrey S MartiniChief Scientific OfficerSale plan1,650$164.14$271KForm 4
Nov 11, 2026Jeffrey S MartiniChief Scientific OfficerSale plan1,467$165.78$243KForm 4
Nov 11, 2026Jeffrey S MartiniChief Scientific OfficerSale plan1,133$166.76$189KForm 4
Nov 11, 2026Jeffrey S MartiniChief Scientific OfficerSale plan1,200$167.75$201KForm 4
Nov 11, 2026Jeffrey S MartiniChief Scientific OfficerSale plan600$168.73$101KForm 4
Nov 11, 2026Jeffrey S MartiniChief Scientific OfficerSale plan200$169.78$34KForm 4
Nov 10, 2026Jeffrey S MartiniChief Scientific OfficerSale plan100$163.34$16.3KForm 4
Nov 10, 2026Jeffrey S MartiniChief Scientific OfficerSale plan1,449$164.85$239KForm 4
Nov 10, 2026Jeffrey S MartiniChief Scientific OfficerSale plan1,651$165.85$274KForm 4
Nov 10, 2026Jeffrey S MartiniChief Scientific OfficerSale plan1,500$166.91$250KForm 4
Nov 10, 2026Jeffrey S MartiniChief Scientific OfficerSale plan200$167.81$33.6KForm 4
Nov 10, 2026Jeffrey S MartiniChief Scientific OfficerSale plan550$169.03$93KForm 4
Nov 10, 2026Jeffrey S MartiniChief Scientific OfficerSale plan800$172.12$138KForm 4
Oct 21, 2026Kathleen GoinChief Operating OfficerSale plan2,043$123.62$253KForm 4
Oct 21, 2026Kathleen GoinChief Operating OfficerSale plan1,663$125.16$208KForm 4
Oct 21, 2026Kathleen GoinChief Operating OfficerSale plan607$126.19$76.6KForm 4
Oct 14, 2026George M JenkinsDirectorSale plan476$121.14$57.7KForm 4
Oct 14, 2026George M JenkinsDirectorSale plan2,072$122.62$254KForm 4
Oct 14, 2026George M JenkinsDirectorSale plan2,604$123.29$321KForm 4
Oct 14, 2026George M JenkinsDirectorSale plan920$124.37$114KForm 4
Oct 14, 2026George M JenkinsDirectorSale plan597$125.33$74.8KForm 4
Oct 14, 2026George M JenkinsDirectorSale plan505$126.55$63.9KForm 4
Oct 13, 2026George M JenkinsDirectorSale plan2,004$128.52$258KForm 4
Oct 13, 2026George M JenkinsDirectorSale plan1,644$129.23$212KForm 4
Oct 13, 2026George M JenkinsDirectorSale plan990$130.48$129KForm 4
Oct 13, 2026George M JenkinsDirectorSale plan1,035$131.49$136KForm 4
Oct 13, 2026George M JenkinsDirectorSale plan579$132.40$76.7KForm 4
Oct 13, 2026George M JenkinsDirectorSale plan922$133.72$123KForm 4
Oct 12, 2026George M JenkinsDirectorSale plan5,095$132.62$676KForm 4
Oct 12, 2026George M JenkinsDirectorSale plan2,458$133.25$328KForm 4
Oct 12, 2026George M JenkinsDirectorSale plan3,335$134.21$448KForm 4
Oct 12, 2026George M JenkinsDirectorSale plan1,447$135.50$196KForm 4
Oct 12, 2026George M JenkinsDirectorSale plan817$136.44$111KForm 4
Sep 16, 2026Kathleen GoinChief Operating OfficerSale plan1,654$153.24$253KForm 4
Sep 16, 2026Kathleen GoinChief Operating OfficerSale plan989$152.36$151KForm 4
Sep 16, 2026Kathleen GoinChief Operating OfficerSale plan1,659$151.16$251KForm 4
Sep 15, 2026George M JenkinsDirectorSale plan560$151.33$84.7KForm 4
Sep 15, 2026George M JenkinsDirectorSale plan954$149.38$143KForm 4
Sep 15, 2026George M JenkinsDirectorSale plan263$150.40$39.6KForm 4
Sep 14, 2026George M JenkinsDirectorSale plan5,632$151.46$853KForm 4
Sep 14, 2026George M JenkinsDirectorSale plan6,160$152.12$937KForm 4
Sep 14, 2026George M JenkinsDirectorSale plan1,560$153.10$239KForm 4
Sep 11, 2026George M JenkinsDirectorSale plan1,274$153.06$195KForm 4
Sep 11, 2026George M JenkinsDirectorSale plan4,577$151.72$694KForm 4
Sep 11, 2026George M JenkinsDirectorSale plan6,520$150.62$982KForm 4
Sep 2, 2026Christopher P KiritsyDirectorSale313$157.00$49.1KForm 4
Aug 19, 2026Kathleen GoinChief Operating OfficerSale plan102$155.59$15.9KForm 4
Aug 19, 2026Kathleen GoinChief Operating OfficerSale plan400$153.00$61.2KForm 4
Aug 19, 2026Kathleen GoinChief Operating OfficerSale plan1,998$151.80$303KForm 4
Aug 19, 2026Kathleen GoinChief Operating OfficerSale plan1,500$151.39$227KForm 4
Aug 19, 2026Kathleen GoinChief Operating OfficerSale plan302$156.77$47.3KForm 4
Jul 15, 2026Kathleen GoinChief Operating OfficerSale plan1,911$150.25$287KForm 4
Jul 15, 2026Kathleen GoinChief Operating OfficerSale plan1,029$149.27$154KForm 4
Jul 15, 2026Kathleen GoinChief Operating OfficerSale plan840$148.40$125KForm 4
Jul 15, 2026Kathleen GoinChief Operating OfficerSale plan522$147.14$76.8KForm 4
Jun 17, 2026Kathleen GoinChief Operating OfficerSale plan25$112.23$2.8KForm 4
Jun 17, 2026Kathleen GoinChief Operating OfficerSale plan2,390$110.26$264KForm 4
Jun 17, 2026Kathleen GoinChief Operating OfficerSale plan1,887$111.31$210KForm 4
May 20, 2026Kathleen GoinChief Operating OfficerSale plan48$111.90$5.4KForm 4
May 20, 2026Kathleen GoinChief Operating OfficerSale plan3,363$110.35$371KForm 4
May 20, 2026Kathleen GoinChief Operating OfficerSale plan891$111.30$99.2KForm 4
Apr 15, 2026Kathleen GoinChief Operating OfficerSale plan100$130.33$13KForm 4
Apr 15, 2026Kathleen GoinChief Operating OfficerSale plan639$129.17$82.5KForm 4
Apr 15, 2026Kathleen GoinChief Operating OfficerSale plan561$128.23$71.9KForm 4
Apr 15, 2026Kathleen GoinChief Operating OfficerSale plan1,500$127.13$191KForm 4
Apr 15, 2026Kathleen GoinChief Operating OfficerSale plan1,502$125.96$189KForm 4
Mar 30, 2026George M JenkinsDirectorPurchase445$112.30$50KForm 4
Mar 18, 2026Kathleen GoinChief Operating OfficerSale plan2,268$117.56$267KForm 4
Mar 18, 2026Kathleen GoinChief Operating OfficerSale plan1,730$118.37$205KForm 4
Mar 18, 2026Kathleen GoinChief Operating OfficerSale plan304$119.08$36.2KForm 4
Feb 27, 2026George M JenkinsDirectorPurchase4,000$125.00$500KForm 4
Feb 27, 2026Elaine J HeronDirectorPurchase2,400$125.00$300KForm 4
Feb 18, 2026Kathleen GoinChief Operating OfficerSale plan3,026$79.16$240KForm 4
Feb 18, 2026Kathleen GoinChief Operating OfficerSale plan1,276$79.97$102KForm 4
Jan 21, 2026Kathleen GoinChief Operating OfficerSale plan3,749$97.94$367KForm 4
Jan 21, 2026Kathleen GoinChief Operating OfficerSale plan553$95.49$52.8KForm 4
Dec 17, 2025Kathleen GoinChief Operating OfficerSale plan4,302$96.47$415KForm 4
Nov 19, 2025Kathleen GoinChief Operating OfficerSale plan2,802$86.51$242KForm 4
Nov 19, 2025Kathleen GoinChief Operating OfficerSale plan1,500$85.72$129KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
George M JenkinsDirector$550K$7.7MOct 14, 2026
Kathleen GoinChief Operating Officer–$6MOct 21, 2026
Jeffrey S MartiniChief Scientific Officer–$2.1MNov 11, 2026
Elaine J HeronDirector$300K–Feb 27, 2026
Christopher P KiritsyDirector–$49.1KSep 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PVLA short interest

High short interest. 18.1% of PVLA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 21%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.60M PVLA shares were sold short, 18.1% of the shares outstanding, up 8.1% from the report before. At the average daily volume of 226,984 shares, buying them all back would take about 11.5 trading days (days to cover).

Shares short, % of all shares

18.1%May 15Oct 3018.6%

Days to cover

11.5May 15Oct 3013.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.60M18.06%+8%226,98411.5
Oct 15, 20262.41M16.71%-5%244,8609.8
Sep 30, 20262.52M17.52%+9%236,25610.7
Sep 15, 20262.33M16.14%+2%181,43612.8
Aug 31, 20262.29M15.90%+7%205,61311.1
Aug 14, 20262.15M14.92%+4%167,91812.8
Jul 31, 20262.07M14.35%-5%224,4969.2
Jul 15, 20262.18M15.21%-8%237,9139.2
Jun 30, 20262.37M16.53%+14%374,7856.3
Jun 15, 20262.08M14.51%-2%317,8526.5
May 29, 20262.12M14.80%-1%171,80512.3
May 15, 20262.15M15.01%-1%242,1478.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Palvella Therapeutics company events

Palvella Therapeutics filed 20 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 28, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing and granted Priority Review to the Company’s New Drug Application for QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. Filing
  3. Aug 4, 2026ResultsReleased financial results. Filing
  4. Jul 14, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
  5. Jun 30, 2026LeadershipThe Board of Directors of Palvella Therapeutics, Inc. increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Pauls, to serve as a Class I director, with an initial term expiring at the Company’s… Filing
  6. Jun 16, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Palvella Therapeutics, Inc., the Company’s stockholders approved the amendment to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable thereunder by 750,000 shares. Filing
  7. May 20, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing that new positive clinical data and findings from the Company’s Phase 3 SELVA and Phase 2 TOIVA studies were reported at the International Society for the Study of Vascular Anomalies World Congress 2026. Filing
  8. May 15, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing that new data from the Company’s Phase 2 TOIVA trial of QTORIN™ rapamycin in patients with cutaneous venous malformations were presented at the 83rd Annual Meeting of the Society for Investigative Dermatology. Filing
  9. May 13, 2026AnnouncementPalvella Therapeutics, Inc. received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective with the open of business on May 13, 2026. Filing
  10. May 7, 2026ResultsReleased financial results. Filing
  11. Apr 13, 2026LeadershipThe Board of Directors of Palvella Therapeutics, Inc. increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed John Doux, M.D., to serve as a Class III director, with an initial term expiring at the Company’s… Filing
  12. Apr 7, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
  13. Mar 31, 2026ResultsReleased financial results. Filing
  14. Feb 26, 2026AgreementPalvella Therapeutics, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives of the underwriters listed in Schedule A thereto, pursuant to which the Company agreed to issue and sell an… Filing
  15. Feb 24, 2026ResultsReleased financial results. Filing
  16. Feb 24, 2026AnnouncementShared information with investors. Filing
  17. Feb 24, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing positive topline results from the Company’s Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. Filing
  18. Jan 29, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
  19. Jan 12, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
  20. Dec 15, 2025AnnouncementThe Company issued a press release announcing positive topline results from the Company’s ongoing Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Palvella Therapeutics financials

Famous investors that hold PVLA

2 of the 50 well-known investors we track reported holding PVLA in their latest 13F filing. The largest position is Jim Simons's, worth $5.1M.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202637,270$5.1M0.0%-30%
Israel Englander · Millennium ManagementQ3 202619,147$2.6M0.0%-63%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PVLA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Frazier Life Sciences Public Fund, L.P.13G/A5.9%
Nov 16, 2026Frazier Life Sciences Public Fund, L.P.13G/A5.9%
Oct 28, 2026Jennison Associates LLC13G/A7.7%
Oct 28, 2026Jennison Associates LLC13G/A7.7%

Questions about Palvella Therapeutics, Inc. (PVLA) stock

Are PVLA insiders buying or selling?

In the last 12 months, PVLA insiders reported 3 open-market purchases worth $850K and 76 sales worth $15.9M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in PVLA?

As of Oct 30, 2026, 2.60M PVLA shares were sold short, 18.1% of the shares outstanding, up 8.1% from the report before. At the average daily volume of 226,984 shares, buying them all back would take about 11.5 trading days (days to cover). See the history.

Which famous investors hold PVLA?

2 of the 50 well-known investors we track reported PVLA in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $5.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.